Low omega-6 vs. low omega-6 plus high omega-3 dietary intervention for Chronic Daily Headache: Protocol for a randomized clinical trial

Trials

Volumn 12, Issue , 2011, Pages

  Ramsden, Christopher E ^a,b   Mann, J Douglas ^b   Faurot, Keturah R ^b   Lynch, Chanee ^b   Imam, Syed T ^b   MacIntosh, Beth A ^c   Hibbeln, Joseph R ^a   Loewke, James ^a   Smith, Sunyata ^b   Coble, Rebecca ^b   Suchindran, Chirayath ^d   Gaylord, Susan A ^b  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d IL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; LINOLEIC ACID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID;

ADULT; ARTICLE; CHRONIC DAILY HEADACHE; CLINICAL PROTOCOL; COMPARATIVE EFFECTIVENESS; ERYTHROCYTE; FAT INTAKE; FATTY ACID BLOOD LEVEL; FATTY ACID METABOLISM; FOOD COMPOSITION; HUMAN; MAJOR CLINICAL STUDY; NUTRITIONAL COUNSELING; PAIN ASSESSMENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; CHRONIC DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIET THERAPY; FEMALE; HEADACHE; MALE; PATIENT COMPLIANCE;

CHRONIC DISEASE; CLINICAL PROTOCOLS; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; FATTY ACIDS, OMEGA-6; FEMALE; HEADACHE; HUMANS; MALE; PATIENT COMPLIANCE;

EID: 79955085485     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-12-97     Document Type: Article

References (58)

1. Scher AI, Stewart WF, Liberman J, Lipton RB. Prevalence of frequent headache in a population sample. Headache 1998, 38(7):497-506. 10.1046/j.1526-4610.1998.3807497.x, 15613165.
2. Castillo J, Munoz P, Guitera V, Pascual J. Kaplan Award 1998. Epidemiology of chronic daily headache in the general population. Headache 1999, 39(3):190-196. 10.1046/j.1526-4610.1999.3903190.x, 15613213.
3. Stovner L, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A, Steiner T, Zwart JA. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 2007, 27(3):193-210. 10.1111/j.1468-2982.2007.01288.x, 17381554.
4. Saper JR. Chronic daily headache: transformational migraine, chronic migraine, and related disorders. Current neurology and neuroscience reports 2008, 8(2):100-107. 10.1007/s11910-008-0017-y, 18460277.
5. Coeytaux RR, Linville JC. Chronic daily headache in a primary care population: prevalence and headache impact test scores. Headache 2007, 47(1):7-12. 10.1111/j.1526-4610.2007.00647.x, 17355488.
6. Nappi G, Perrotta A, Rossi P, Sandrini G. Chronic daily headache. Expert Rev Neurother 2008, 8(3):361-384. 10.1586/14737175.8.3.361, 18345968.
7. Dodick DW. Clinical practice. Chronic daily headache. The New England journal of medicine 2006, 354(2):158-165. 10.1056/NEJMcp042897, 16407511.
8. Pryse-Phillips W. Assessment and management of disability in chronic daily headache. Current pain and headache reports 2005, 9(1):53-58. 10.1007/s11916-005-0075-7, 15625026.
9. Cady R, Farmer K, Dexter JK, Schreiber C. Cosensitization of pain and psychiatric comorbidity in chronic daily headache. Current pain and headache reports 2005, 9(1):47-52. 10.1007/s11916-005-0074-8, 15625025.
10. Cady R, Schreiber C, Farmer K, Sheftell F. Primary headaches: a convergence hypothesis. Headache 2002, 42(3):204-216. 10.1046/j.1526-4610.2002.02053.x, 11903544.
11. Vonkeman HE, Klok RM, Postma MJ, Brouwers JR, van de Laar MA. Direct medical costs of serious gastrointestinal ulcers among users of NSAIDs. Drugs & aging 2007, 24(8):681-690.
12. Maizels M. The patient with daily headaches. American family physician 2004, 70(12):2299-2306.
13. Yurekli VA, Akhan G, Kutluhan S, Uzar E, Koyuncuoglu HR, Gultekin F. The effect of sodium valproate on chronic daily headache and its subgroups. The journal of headache and pain 2008, 9(1):37-41. 10.1007/s10194-008-0002-5, 18231713.
14. Park SP, Kwon SH. Cognitive effects of antiepileptic drugs. Journal of clinical neurology (Seoul, Korea) 2008, 4(3):99-106. 10.3988/jcn.2008.4.3.99, 2686875, 19513311.
15. Solomon GD. Reducing the cost of headache medication. Current pain and headache reports 2009, 13(3):227-230. 10.1007/s11916-009-0038-5, 19457284.
16. Meng ID, Cao L. From migraine to chronic daily headache: the biological basis of headache transformation. Headache 2007, 47(8):1251-1258. 10.1111/j.1526-4610.2007.00907.x, 17883547.
17. Richards DA, Bliss TV, Richards CD. Differential modulation of NMDA-induced calcium transients by arachidonic acid and nitric oxide in cultured hippocampal neurons. Eur J Neurosci 2003, 17(11):2323-2328. 10.1046/j.1460-9568.2003.02671.x, 12814365.
18. Casado M, Ascher P. Opposite modulation of NMDA receptors by lysophospholipids and arachidonic acid: common features with mechanosensitivity. J Physiol 1998, 513(Pt 2):317-330. 10.1111/j.1469-7793.1998.317bb.x, 2231302, 9806985.
19. Petrenko AB, Yamakura T, Baba H, Shimoji K. The role of N-methyl-D-aspartate (NMDA) receptors in pain: a review. Anesth Analg 2003, 97(4):1108-1116. 10.1213/01.ANE.0000081061.12235.55, 14500166.
20. Navarrete M, Araque A. Endocannabinoids mediate neuron-astrocyte communication. Neuron 2008, 57(6):883-893. 10.1016/j.neuron.2008.01.029, 18367089.
21. Yang H, Chen C. Cyclooxygenase-2 in synaptic signaling. Current pharmaceutical design 2008, 14(14):1443-1451. 10.2174/138161208784480144, 2561288, 18537667.
22. Yang H, Zhang J, Breyer RM, Chen C. Altered hippocampal long-term synaptic plasticity in mice deficient in the PGE2 EP2 receptor. J Neurochem 2009, 108(1):295-304. 10.1111/j.1471-4159.2008.05766.x, 2605769, 19012750.
23. Grant I, Cahn BR. Cannabis and endocannabinoid modulators: Therapeutic promises and challenges. Clinical neuroscience research 2005, 5(2-4):185-199. 10.1016/j.cnr.2005.08.015, 2544377, 18806886.
24. Wienecke T, Olesen J, Oturai PS, Ashina M. Prostaglandin E2(PGE2) induces headache in healthy subjects. Cephalalgia . 2009, 29(5):509-519.
25. Akerman S, Kaube H, Goadsby PJ. Anandamide acts as a vasodilator of dural blood vessels in vivo by activating TRPV1 receptors. British journal of pharmacology 2004, 142(8):1354-1360. 10.1038/sj.bjp.0705896, 1575202, 15277315.
26. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, Di Marzo V, Julius D, Hogestatt ED. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999, 400(6743):452-457. 10.1038/22761, 10440374.
27. Peroni RN, Orliac ML, Becu-Villalobos D, Huidobro-Toro JP, Adler-Graschinsky E, Celuch SM. Sex-linked differences in the vasorelaxant effects of anandamide in vascular mesenteric beds: role of oestrogens. European journal of pharmacology 2004, 493(1-3):151-160. 10.1016/j.ejphar.2004.04.031, 15189776.
28. Ramsden CE, Gagnon C, Graciosa J, Faurot KR, David R, Brailey JA, Harden RN. Do omega-6 and trans fatty acids play a role in complex regional pain syndrome? A pilot study. Pain medicine (Malden, Mass) 2010,
29. Li B, Birdwell C, Whelan J. Antithetic relationship of dietary arachidonic acid and eicosapentaenoic acid on eicosanoid production in vivo. J Lipid Res 1994, 35(10):1869-1877.
30. Salem N, Pawlosky R, Wegher B, Hibbeln J. In vivo conversion of linoleic acid to arachidonic acid in human adults. Prostaglandins, leukotrienes, and essential fatty acids 1999, 60(5-6):407-410. 10.1016/S0952-3278(99)80021-0, 10471130.
31. Lands WE, Libelt B, Morris A, Kramer NC, Prewitt TE, Bowen P, Schmeisser D, Davidson MH, Burns JH. Maintenance of lower proportions of (n - 6) eicosanoid precursors in phospholipids of human plasma in response to added dietary (n - 3) fatty acids. Biochim Biophys Acta 1992, 1180(2):147-162.
32. Xu ZZ, Zhang L, Liu T, Park JY, Berta T, Yang R, Serhan CN, Ji RR. Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nature medicine 16(5):592-597. 591p following 597, 10.1038/nm.2123, 2866054, 20383154.
33. Pocock SJ. Allocation of patients to treatment in clinical trials. Biometrics 1979, 35(1):183-197. 10.2307/2529944, 497334.
34. Mann JD, Faurot KR, Wilkinson L, Curtis P, Coeytaux RR, Suchindran C, Gaylord SA. Craniosacral therapy for migraine: protocol development for an exploratory controlled clinical trial. BMC complementary and alternative medicine 2008, 8:28. 10.1186/1472-6882-8-28, 2442042, 18541041.
35. Kosinski M, Bayliss MS, Bjorner JB, Ware JE, Garber WH, Batenhorst A, Cady R, Dahlof CG, Dowson A, Tepper S. A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res 2003, 12(8):963-974. 10.1023/A:1026119331193, 14651415.
36. Kawata AK, Coeytaux RR, Devellis RF, Finkel AG, Mann JD, Kahn K. Psychometric properties of the HIT-6 among patients in a headache-specialty practice. Headache 2005, 45(6):638-643. 10.1111/j.1526-4610.2005.05130.x, 15953295.
37. Stewart WF, Lipton RB, Kolodner KB, Sawyer J, Lee C, Liberman JN. Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain 2000, 88(1):41-52. 10.1016/S0304-3959(00)00305-5, 11098098.
38. Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology 2001, 56(6 (Suppl 1)):S20-28.
39. Lipton RB, Stewart WF, Sawyer J, Edmeads JG. Clinical utility of an instrument assessing migraine disability: the Migraine Disability Assessment (MIDAS) questionnaire. Headache 2001, 41(9):854-861.
40. Ware J, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996, 34(3):220-233. 10.1097/00005650-199603000-00003, 8628042.
41. Luo X, Lynn George M, Kakouras I, Edwards CL, Pietrobon R, Richardson W, Hey L. Reliability, validity, and responsiveness of the short form 12-item survey (SF-12) in patients with back pain. Spine 2003, 28(15):1739-1745.
42. Lipton RB, Hamelsky SW, Kolodner KB, Steiner TJ, Stewart WF. Migraine, quality of life, and depression: a population-based case-control study. Neurology 2000, 55(5):629-635.
43. Derogatis LR. BSI-18: Administration, Scoring, and Procedures Manual. 2000, Minneapolis, MN: National Computer Systems.
44. Derogatis LR, Melisaratos N. The Brief Symptom Inventory: an introductory report. Psychol Med 1983, 13(3):595-605. 10.1017/S0033291700048017, 6622612.
45. Borkovec TD, Nau SD. Credibility of analogue therapy rationales. J Behav Therap & Exp Psychiat 1972, 3:257-260.
46. Devilly GJ, Borkovec TD. Psychometric properties of the credibility/expectancy questionnaire. J Behav Ther Exper Psychiat 2000, 31:73-86.
47. Kalauokalani D, Cherkin DC, Sherman KJ, Koepsell TD, Deyo RA. Lessons from a trial of acupuncture and massage for low back pain: patient expectations and treatment effects. Spine 2001, 26(13):1418-1424. 10.1097/00007632-200107010-00005, 11458142.
48. Linde K, Witt CM, Streng A, Weidenhammer W, Wagenpfeil S, Brinkhaus B, Willich SN, Melchart D. The impact of patient expectations on outcomes in four randomized controlled trials of acupuncture in patients with chronic pain. Pain 2007, 128(3):264-271. 10.1016/j.pain.2006.12.006, 17257756.
49. Patwardhan AM, Scotland PE, Akopian AN, Hargreaves KM. Activation of TRPV1 in the spinal cord by oxidized linoleic acid metabolites contributes to inflammatory hyperalgesia. Proc Natl Acad Sci USA 2009, 106(44):18820-18824. 10.1073/pnas.0905415106, 2764734, 19843694.
50. Patwardhan AM, Akopian AN, Ruparel NB, Diogenes A, Weintraub ST, Uhlson C, Murphy RC, Hargreaves KM. Heat generates oxidized linoleic acid metabolites that activate TRPV1 and produce pain in rodents. The Journal of clinical investigation 120(5):1617-1626. 10.1172/JCI41678, 2860941, 20424317.
51. Gunthorpe MJ, Chizh BA. Clinical development of TRPV1 antagonists: targeting a pivotal point in the pain pathway. Drug discovery today 2009, 14(1-2):56-67. 10.1016/j.drudis.2008.11.005, 19063991.
52. Kingsbury KJ, Paul S, Crossley A, Morgan DM. The fatty acid composition of human depot fat. Biochem J 1961, 78:541-550. 1205373, 13756126.
53. Kingsbury KJ, Heyes TD, Morgan DM, Aylot C, Burton PA, Emmerson R, Robinson PJ. The effect of dietary changes on the fatty acid composition of normal human depot fat. Biochem J 1962, 84:124-133. 1243631, 14456141.
54. Garland M, Sacks FM, Colditz GA, Rimm EB, Sampson LA, Willett WC, Hunter DJ. The relation between dietary intake and adipose tissue composition of selected fatty acids in US women. Am J Clin Nutr 1998, 67(1):25-30.
55. Blasbalg T, Hibbeln JR, Ramsden CE. Changes in consumption of n-3 and n-6 fatty acids in the 20th century. Bethesda, MD 2010,
56. Hodson L, Skeaff CM, Fielding BA. Fatty acid composition of adipose tissue and blood in humans and its use as a biomarker of dietary intake. Prog Lipid Res 2008, 47(5):348-380. 10.1016/j.plipres.2008.03.003, 18435934.
57. Katan MB, Deslypere JP, van Birgelen AP, Penders M, Zegwaard M. Kinetics of the incorporation of dietary fatty acids into serum cholesteryl esters, erythrocyte membranes, and adipose tissue: an 18-month controlled study. J Lipid Res 1997, 38(10):2012-2022.
58. Thomas EL, Frost G, Barnard ML, Bryant DJ, Taylor-Robinson SD, Simbrunner J, Coutts GA, Burl M, Bloom SR, Sales KD, et al. An in vivo 13C magnetic resonance spectroscopic study of the relationship between diet and adipose tissue composition. Lipids 1996, 31(2):145-151. 10.1007/BF02522613, 8835401.